| Market Cap | 587.25M | P/E | - | EPS this Y | 13.60% | Ern Qtrly Grth | - |
| Income | -44.05M | Forward P/E | -4.76 | EPS next Y | -41.20% | 50D Avg Chg | 1.00% |
| Sales | 15.13M | PEG | -0.28 | EPS past 5Y | - | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 1.72 | EPS next 5Y | 145.30% | 52W High Chg | -46.00% |
| Recommedations | 1.60 | Quick Ratio | 57.03 | Shares Outstanding | 52.16M | 52W Low Chg | 28.00% |
| Insider Own | 9.27% | ROA | -7.98% | Shares Float | 32.13M | Beta | 3.57 |
| Inst Own | 98.39% | ROE | -9.20% | Shares Shorted/Prior | 3.31M/3.25M | Price | 12.77 |
| Gross Margin | -251.04% | Profit Margin | -291.17% | Avg. Volume | 152,358 | Target Price | 67.50 |
| Oper. Margin | -155.36% | Earnings Date | Aug 7 | Volume | 62,386 | Change | -3.55% |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Reardon Tighe | Acting Chief Financi.. Acting Chief Financial Officer | Nov 13 | Buy | 5.87 | 849,854 | 4,988,643 | 849,854 | 11/15/23 |
| Lichter Jay | Director Director | Nov 13 | Buy | 5.87 | 849,854 | 4,988,643 | 849,854 | 11/15/23 |
| Avalon Ventures XI, L.P. | 10% Owner 10% Owner | Nov 13 | Buy | 5.87 | 849,854 | 4,988,643 | 849,854 | 11/13/23 |
| ORBIMED ADVISORS LLC | Director Director | Dec 29 | Sell | 20.3 | 40,400 | 820,120 | 231,098 | 12/30/21 |
| Thompson Peter A. | Director Director | Dec 29 | Sell | 20.3 | 40,400 | 820,120 | 231,098 | 12/30/21 |